Researchers at MedUni Vienna, led by Lukas Kenner, have identified mutations in the KMT2C protein as a significant factor in the progression of prostate cancer. Their study, published in Molecular Cancer, reveals that alterations in KMT2C disrupt its regulatory functions, leading to the activation of the oncogene MYC, which promotes rapid cell division and metastasis. This discovery enhances the understanding of how prostate cancer advances from a localized condition to a more aggressive, life-threatening disease.
The implications of this research are substantial for both diagnosis and treatment. The team proposes the development of a blood test to detect KMT2C mutations, facilitating early identification of patients at higher risk for aggressive prostate cancer. Additionally, the findings suggest that MYC inhibitors, currently under clinical investigation, could serve as effective therapies for advanced stages of the disease. This breakthrough offers promising avenues for personalized medical approaches, aiming to improve outcomes for those affected by metastatic prostate cancer. Click for More Details
